Monday, November 16, 2026
18.4 C
Bengaluru

Rx 2024 – Top 25 Drugs by Sales, Growth & Market Trends

The pharmaceutical market in 2024 saw major shifts driven by obesity, diabetes, and oncology treatments. Leading products like Merck’s Keytruda and Novo Nordisk’s Ozempic continued to dominate, while new entrants such as Eli Lilly’s Mounjaro and Zepbound reshaped the market with unprecedented growth. Here's a deep dive into the top 25 best-selling prescription drugs of the year by total sales and growth rate.

Top 25 Prescription Drugs by Global Sales in 2024

RankDrugCompany2024 Sales (USD)1KeytrudaMerck$29.5B2OzempicNovo Nordisk$17.5B3MounjaroEli Lilly$11.5B4EliquisBMS/Pfizer$11.4B5BiktarvyGilead Sciences$10.8B6DupixentSanofi/Regeneron$10.7B7DarzalexJohnson & Johnson$10.4B8StelaraJohnson & Johnson$9.7B9OpdivoBristol Myers Squibb$9.3B10TrulicityEli Lilly$8.7B11ImbruvicaAbbVie/J&J$8.3B12EntrestoNovartis$7.7B13IbrancePfizer$7.1B14RevlimidBristol Myers Squibb$6.9B15XareltoBayer/J&J$6.8B16OcrevusRoche$6.6B17TecentriqRoche$6.4B18VekluryGilead Sciences$6.2B19SkyriziAbbVie$6.0B20CosentyxNovartis$5.8B21JanuviaMerck$5.6B22SymbicortAstraZeneca$5.4B23FarxigaAstraZeneca$5.2B24ZepboundEli Lilly$5.0B25TremfyaJohnson & Johnson$4.8B

Top 25 Prescription Drugs by Growth Rate in 2024

RankDrugCompanyGrowth RateNotes1MounjaroEli Lilly+969%Massive expansion2SkyriziAbbVie+50.3%Strong immunology push3OzempicNovo Nordisk+38%Diabetes/obesity boom4DupixentSanofi/Regeneron+33.6%Consistent uptake5EntrestoNovartis+30%Heart failure growth6DarzalexJ&J+22.1%Oncology expansion7KeytrudaMerck+18%Leading cancer therapy8OcrevusRoche+16%Multiple sclerosis market9BiktarvyGilead+14%HIV dominance10StelaraJ&J+11.7%Immunology retention11OpdivoBristol Myers+9.2%Oncology growth12TremfyaJ&J+8% (est.)Psoriasis/arthritis13FarxigaAstraZeneca+6.1%Broad CV/metabolic use14TrulicityEli Lilly+4.1%GLP-1 growth15EliquisBMS/Pfizer+3.5%Stable anticoagulant16CosentyxNovartis+2% (est.)Immunology17TecentriqRoche~0% (est.)Plateauing growth18IbrancePfizer−1% (est.)Mature breast cancer19SymbicortAstraZeneca−2% (est.)Generic erosion20XareltoBayer/J&J−5.8%Competitive pressure21VekluryGilead−15% (est.)COVID-19 decline22JanuviaMerck−10% (est.)Patent loss23ImbruvicaAbbVie/J&J−17.9%Market erosion24RevlimidBMS−38.6%Major LOE hit25ZepboundEli LillyN/ALaunched late 2023

Free Membership Required

You must be a Free member to access this content.

Join Now

Already a member? Log in here

Hot this week

Evonile Pharma: The Real Bet Is Not the Acquisition. It is the Field Force.

ChrysCapital’s acquisition of Novartis India and its transformation into...

Closing the Value Gap in Indian Pharma: What Doctors Really Want from Digital Engagement

Indian pharma is investing heavily in digital engagement. But...

Indian Pharma 2026: The Growth Engine Is Changing

The Indian Pharmaceutical Market isn't just growing. Its centre...

Anand Shetty Appointed CEO – Emerging Markets at Cadila Pharmaceuticals

Cadila Pharmaceuticals has appointed Anand Shetty as Chief Executive...

The paradox of the “Pharmacy of the World.” 💊

India has world-scale formulation capability, yet the chemistry beneath...

Topics

Evonile Pharma: The Real Bet Is Not the Acquisition. It is the Field Force.

ChrysCapital’s acquisition of Novartis India and its transformation into...

Indian Pharma 2026: The Growth Engine Is Changing

The Indian Pharmaceutical Market isn't just growing. Its centre...

Anand Shetty Appointed CEO – Emerging Markets at Cadila Pharmaceuticals

Cadila Pharmaceuticals has appointed Anand Shetty as Chief Executive...

The paradox of the “Pharmacy of the World.” 💊

India has world-scale formulation capability, yet the chemistry beneath...

The Innovator’s Gene and the Generic’s Promise

A medicine must first be discovered. It must then...

Private Equity in Indian Healthcare: Who Is Investing Beyond the Metros?

Private capital is transforming India's healthcare landscape. But is...
spot_img

Related Articles

spot_imgspot_img